Persium Advisors LLC Takes $495,000 Position in Pfizer Inc. (NYSE:PFE)

Persium Advisors LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 19,534 shares of the biopharmaceutical company’s stock, valued at approximately $495,000.

A number of other institutional investors have also recently added to or reduced their stakes in PFE. Mcdonald Partners LLC raised its holdings in shares of Pfizer by 9.9% during the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after acquiring an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust purchased a new stake in shares of Pfizer during the fourth quarter worth approximately $264,000. Harvey Capital Management Inc. acquired a new position in Pfizer in the 4th quarter valued at $544,000. ING Groep NV lifted its holdings in Pfizer by 48.6% in the 4th quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company’s stock valued at $26,881,000 after purchasing an additional 331,403 shares in the last quarter. Finally, WCM Investment Management LLC boosted its stake in Pfizer by 128.7% during the 4th quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company’s stock worth $3,062,000 after purchasing an additional 65,238 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.0%

Shares of PFE opened at $23.36 on Friday. The company’s 50-day moving average price is $22.95 and its 200 day moving average price is $25.00. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $132.81 billion, a P/E ratio of 16.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm earned $0.82 EPS. The business’s revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.36%. Pfizer’s dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

PFE has been the subject of a number of recent research reports. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group boosted their target price on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.